Our mission is to transform the discovery and development of therapeutic monoclonal antibodies.
ÀÖ²¥´«Ã½ University Therapeutic Antibody Centre
About us
ÀÖ²¥´«Ã½ University Therapeutic Antibody Centre (NUTAC) is dedicated to producing novel therapeutic monoclonal antibodies (mAbs) for the treatment of cancer and infectious disease. It is a newly established unit, based on Professor Lindy Durrant’s track record for delivering innovative immunotherapeutic products to the clinic. Lindy Durrant is a Professor in Cancer Immunotherapy at the University and the CEO of Scancell Limited, the University spin-out company she established in 1997.
The mAb group at NUTAC have recently developed a technology to unlock the glycome to allow for the production of anti-glycan mAbs. This has the potential to identify numerous new targets typically missed in conventional screening strategies. Our ability to unlock the glycome presents a unique proposition for the diagnosis, treatment and prevention of disease.
Latest news
Attending BIO 22-25 April
NUTAC will be attending the 2013 BIO International Convention from the 22-25 April at McCormick Place, Chicago, Illinois.